Brokerages Set Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) PT at $72.13

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) has earned a consensus recommendation of “Moderate Buy” from the fifteen research firms that are currently covering the company, Marketbeat reports. Four analysts have rated the stock with a hold rating, ten have issued a buy rating and one has issued a strong buy rating on the company. The average 12 month price objective among brokerages that have covered the stock in the last year is $71.67.

Several analysts have recently commented on the stock. Wedbush lifted their price target on shares of Apellis Pharmaceuticals from $38.00 to $41.00 and gave the company a “neutral” rating in a research report on Friday, August 9th. Robert W. Baird upped their price target on Apellis Pharmaceuticals from $86.00 to $96.00 and gave the company an “outperform” rating in a research note on Friday, August 9th. Wells Fargo & Company cut their price objective on Apellis Pharmaceuticals from $57.00 to $48.00 and set an “equal weight” rating for the company in a research report on Thursday, May 23rd. JPMorgan Chase & Co. decreased their target price on shares of Apellis Pharmaceuticals from $64.00 to $57.00 and set an “overweight” rating on the stock in a research report on Friday. Finally, HC Wainwright dropped their price target on shares of Apellis Pharmaceuticals from $92.00 to $83.00 and set a “buy” rating for the company in a research report on Friday, August 2nd.

Apellis Pharmaceuticals Stock Performance

Shares of Apellis Pharmaceuticals stock opened at $36.31 on Thursday. The business’s 50 day moving average price is $38.13 and its 200 day moving average price is $44.31. The company has a market cap of $4.42 billion, a price-to-earnings ratio of -10.49 and a beta of 0.88. The company has a debt-to-equity ratio of 1.73, a quick ratio of 4.18 and a current ratio of 5.08. Apellis Pharmaceuticals has a one year low of $33.49 and a one year high of $73.80.

Apellis Pharmaceuticals (NASDAQ:APLS) last announced its quarterly earnings results on Thursday, August 1st. The company reported ($0.30) earnings per share for the quarter, beating the consensus estimate of ($0.33) by $0.03. The firm had revenue of $199.70 million for the quarter, compared to analysts’ expectations of $190.89 million. Apellis Pharmaceuticals had a negative net margin of 52.99% and a negative return on equity of 138.32%. The company’s revenue was up 110.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($1.02) EPS. On average, research analysts predict that Apellis Pharmaceuticals will post -1.29 EPS for the current year.

Insider Transactions at Apellis Pharmaceuticals

In related news, Director A. Sinclair Dunlop sold 37,000 shares of the stock in a transaction on Friday, June 21st. The stock was sold at an average price of $39.24, for a total value of $1,451,880.00. Following the transaction, the director now owns 136,998 shares of the company’s stock, valued at $5,375,801.52. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 6.80% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the business. Future Financial Wealth Managment LLC acquired a new stake in Apellis Pharmaceuticals during the 1st quarter worth $29,000. BI Asset Management Fondsmaeglerselskab A S acquired a new stake in shares of Apellis Pharmaceuticals in the 1st quarter valued at about $89,000. nVerses Capital LLC grew its stake in Apellis Pharmaceuticals by 300.0% during the 2nd quarter. nVerses Capital LLC now owns 2,800 shares of the company’s stock worth $107,000 after buying an additional 2,100 shares during the last quarter. CWM LLC boosted its holdings in shares of Apellis Pharmaceuticals by 299.9% in the second quarter. CWM LLC now owns 4,151 shares of the company’s stock valued at $159,000 after acquiring an additional 3,113 shares during the period. Finally, CWA Asset Management Group LLC purchased a new position in shares of Apellis Pharmaceuticals during the fourth quarter worth approximately $205,000. Hedge funds and other institutional investors own 96.29% of the company’s stock.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).